Everolimus - CAS 159351-69-6
Catalog number: 159351-69-6
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) with an immunosuppressive activity which is comparable to that of rapamycin. It inhibits cytokine-mediated lymphocyte proliferation. Everolimus can be used as an immunosuppressant in the treatment of renal cell cancer and other cancers.
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
inhibitor of mTOR, immunosuppressant
Off-White to Pale Yellow Solid
Afinitor; Certican; Zortress; RAD001; SDZ-RAD; 40-O-(2-Hydroxyethyl)rapamycin; 42-O-(2-Hydroxy)ethyl Rapamycin
Soluble in ethanol, methanol, DMF or DMSO. Limited water solubility.
Shelf Life:
2 years
Melting Point:
107-113 °C
Canonical SMILES:
1. Structure guided design of improved anti-proliferative rapalogs through biosynthetic medicinal chemistry
Matthew A. Gregory, Andrew L. Kaja, Barrie Wilkinson*. Chem. Sci., 2013, 4, 1046–1052
Rapamycin is a polyketide natural product produced by Streptomyces rapamycinicus NRRL5491. The intracellular receptor of 1 is the 12 kDa FK506 binding protein,(FKBP12). The 1–FKBP12 complex is a highly selective and potent inhibitor of mammalian/mechanistic target of rapamy- cin complex 1 (mTORC1) at sub-nanomolar concentrations. Rapamycin is used clinically as an immunosuppressant after organ transplantation (Rapamune) and for the prevention of restenosis after stent insertion for the treatment of coronary heart disease (e.g. Cypher).Semi-synthetic derivatives of Rapamycin including temsirolimus (Torisel) and everolimus (Afinitor) are both approved for the treatment of renal cell carcinoma and other proliferative diseases. Further rapamycin analogues (rapalogs) have shown potential for the treatment of cardiovascular, autoimmune and neurodegenerative diseases.
2. Biosynthetic medicinal chemistry of natural product drugs
Frank E. Koehn*. Med. Chem. Commun., 2012, 3, 854–865
Rapamycin (sirolimus) is a 31-membered macrocyclic polyketide produced by Streptomyces hygroscopicus. It was discovered on the basis of its antifungal activity and then soon was shown to have potent anti-proliferative/immunosuppressive effects. Rapamycin and its analogues exert their antiproliferative effect by inhibition of mTOR (mammalian target of rapamycin) via FKBP-12-mediated formation of a ternary complex. The powerful anti-proliferative activity of rapamycin have been harnessed clinically to treat organ transplant rejection, and further development has furnished three semisynthetic analogues- temsirolimus (2) and everolimus (34) which are both approved for treatment of advanced renal cancer, and ridaforolimus (35) which is in late stage clinical trial for the treatment of metastatic soft-tissue and bone cancer. (Fig. 6) In contrast to FK506, rapamycin has been the subject of considerable biosynthetic medicinal investigation, and serves as a good example of what is possible with modular polyketide systems.
3. The metamorphosis of vascular stents: passive structures to smart devices
Purandhi Roopmani, Swaminathan Sethuraman, Santhosh Satheesh and Uma Maheswari Krishnan*. RSC Adv.,2016, 6,2835–2853
The initial success with sirolimus had triggered a search of sirolimus analogues that possess similar anti-proliferative effect but lesser adverse effects. Among these analogues, everolimus (a new macrocylic triene derivative), biolimus A9, immunosuppressive agents such as cyclosporine, mycophenolic acid and tacrolimus, which induce G1 arrest leading to reduced proliferation and immune response, have been incorporated in stents. Everolimus is a macrolide antibiotic that possesses the ability to suppress the immune response and cell proliferation leading to prevention of restenosis similar to sirolimus. It possesses greater polarity than sirolimus and hence has better bioavailability and is rapidly absorbed on the arterial wall and attains peak concentration within few hours thereby offering better efficacy. Experimental data have shown that orally administered everolimus inhibits in-stent neointimal formation and significantly promotes neointimal healing. Evorolimus has been found to act at a later stage than the calcineurin inhibitor cyclosporin and tacrolimus.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mTOR Products

(CAS: 57818-44-7)

ABTL-0812 is an orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR), rictor-mTOR and dihydrofolate reductase with p...

CAS 1009298-59-2 AZD-2014

(CAS: 1009298-59-2)

AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. AZD2014 inhibits the activity o...

CAS 572924-54-0 Ridaforolimus

(CAS: 572924-54-0)

Ridaforolimus is a small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus bin...

CAS 326914-06-1 MHY1485

(CAS: 326914-06-1)

mTOR activator with an inhibitory effect on autophagy. MHY1485 markedly increased the LC3II/LC3I ratio dose-dependently and time-dependently by inhibition of th...

CAS 154447-38-8 LY 303511

LY 303511
(CAS: 154447-38-8)

PI3K inhibitory activity. Inhibits voltage-gated Kv channel activity (IC50 = 64.6 μM). Various pharmacological effects including inhibition of LPS-stimulated FP...

CAS 1222998-36-8 Torin 1

Torin 1
(CAS: 1222998-36-8)

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively.

CAS 1009298-09-2 AZD-8055

(CAS: 1009298-09-2)

AZD-8055 is an inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/t...

(CAS: 1660110-65-5)

SC-III3 is a scopoletin derivative and has been found to induce the autophagy of hepatoma HepG2 cells so that could be significant in anticancer studies.

CAS 159351-69-6 Everolimus

(CAS: 159351-69-6)

Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) with an immunosuppressive activity which is comparable to that of rapamycin. It inhibits cyto...

CAS 1092351-67-1 PP242

(CAS: 1092351-67-1)

PP242 is a novel potent and selective mTOR inhibitor with an IC50 of 8 nM. PP242 also shows residual (micromolar) activity against panel of tyrosine kinases. Bu...

CAS 1223002-54-7 QL-IX-55

(CAS: 1223002-54-7)

The functional target of QL-IX-55 is the ATP-binding site of TOR2 as evidenced by the discovery of resistant alleles of TOR2 through rational design and unbiase...

CAS 162635-04-3 Temsirolimus

(CAS: 162635-04-3)

Temsirolimus potently inhibits mTOR kinase activity with IC50 of 1.76 μM, similar to that of rapamycin with IC50 of 1.74 μM.

CAS 915019-65-7 Dactolisib

(CAS: 915019-65-7)

Dactolisib, also known as BEZ235, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BEZ235 speci...

CC-115 hydrochloride
(CAS: 1300118-55-1)

The hydrochloride salt form of CC-115 which is a mTOR / DNA-PK inhibitor that probably has antineoplastic effect through influencing the cellular proliferation ...

CAS 1033735-94-2 GNE-493

(CAS: 1033735-94-2)

GNE-493 is a potent, selective, and orally available dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/12/16/16/32 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR respectively...

CAS 6724-53-4 Perhexiline maleate salt

Perhexiline maleate salt
(CAS: 6724-53-4)

Perhexiline maleate salt is a carnitine palmitoyltransferase 1 (CPT1) and CPT2 inhibitor. It is an anti-anginal metabolic modulator and used in treatments for a...

CAS 1144068-46-1 WYE-125132

(CAS: 1144068-46-1)

WYE-125132, also known as WYE-132, is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor. WYE-132 inhibited mTORC1 and mTORC2 in diverse canc...

CAS 1032754-93-0 Apitolisib

(CAS: 1032754-93-0)

Apitolisib, also known as GDC-0980 and RG7422;  or GNE390, is a dual PI3 kinase/mTOR inhibitor,   is also an orally available agent targeting phosphatidylinosit...

(CAS: 944153-47-3)

SMER18 is a small molecule enhancer of rapamycin. It act as a mTOR-independent autophagy inducer. It is a positive regulators of autophagy acting independently ...

CAS 1224844-38-5 MLN0128

(CAS: 1224844-38-5)

MLN0128, also known as INK128, is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR co...

Chemical Structure

CAS 159351-69-6 Everolimus

Quick Inquiry

Verification code

Featured Items